tiprankstipranks
Theralase Expands Clinical Trial for Bladder Cancer
Company Announcements

Theralase Expands Clinical Trial for Bladder Cancer

Story Highlights

Theralase Technologies (TSE:TLT) has released an update.

Pick the best stocks and maximize your portfolio:

Theralase Technologies has opened a new clinical study site at St. Joseph’s Healthcare Hamilton in Canada to advance its promising anti-cancer therapy for bladder cancer. The Phase II study has shown that over 68% of treated patients achieved a positive response, highlighting the potential of Theralase’s innovative treatment approach. This progress offers hope for the significant number of bladder cancer patients diagnosed annually in North America.

For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands US Bladder Cancer Study Sites
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands Cancer Study with Promising Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App